Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill

Gilead Sciences is getting world rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to deal with inflammatory bowel illness. It may compete in opposition to Johnson & Johnson’s Icotyde, an oral peptide that blocks the identical goal and can also be in growth for IBD.

The publish Gilead to Pay $1.3B for Oral Peptide That Might Rival J&J’s New Immunology Capsule appeared first on MedCity Information.

Source link